Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06573294 · ClinicalTrials.gov registry record · Phase 1
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
A Phase 1 study of Advanced Malignant Solid Tumors and Metastatic Malignant Solid Tumors, sponsored by Genmab.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT06573294 is a Phase 1 study of Advanced Malignant Solid Tumors and Metastatic Malignant Solid Tumors that is actively recruiting participants, run by Genmab. The registered enrollment target is 45 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT06573294, a Phase 1 study of Advanced Malignant Solid Tumors and Metastatic Malignant Solid Tumors, is actively recruiting participants, sponsored by Genmab.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration for an individual participant will be up to approximately 11 months. * The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months. Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.
Conditions Studied
Interventions
- DRUG GEN1057
- DRUG Premedication
Study Locations (5)
Other
- National Cancer Center, Tsukiji 5-1-1 - Tokyo
- Start Madrid Centro Integral Oncologico Clara Campal CIOCC - Madrid
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Barcelona
- Hospital Universitari Vall d'Hebron - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2027-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06573294
The ClinicalTrials.gov registry entry for NCT06573294 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Malignant Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which GEN1057 is the first listed.
NCT06573294 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT06573294 about?
NCT06573294 is a clinical study titled "Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors". The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration for an individual participant will be up to approximately 11 months. * The treatment duration for an individual participa...
What is the current status of trial NCT06573294?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2024-08-28. Estimated completion is 2027-09-21.
What conditions does trial NCT06573294 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors.
What interventions are being tested in trial NCT06573294?
The interventions under investigation include: GEN1057 (DRUG), Premedication (DRUG).
Who is sponsoring clinical trial NCT06573294?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06573294 being conducted?
This trial has 5 study locations across Tennessee, Texas, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Advanced Malignant Solid Tumors
All registered trials for this condition
Metastatic Malignant Solid Tumors
All registered trials for this condition
Tennessee
All trials with a study site in Tennessee
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.